# Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer

> **NCT03473730** · EARLY_PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Bladder Urothelial Carcinoma
- Clear Cell Renal Cell Carcinoma
- Malignant Urinary System Neoplasm
- Metastatic Kidney Carcinoma
- Stage IV Renal Cell Cancer AJCC V8

## Interventions

- **PROCEDURE:** Biopsy
- **BIOLOGICAL:** Daratumumab
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Metastasectomy
- **PROCEDURE:** Nephrectomy

## Key facts

- **NCT ID:** NCT03473730
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-29
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-01-27
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03473730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03473730, "Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT03473730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*